Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

Multiple System Atrophy ( MSA )

  • Development stage
    Second-phase Investigator-initiated trials(IIT) Completed
  • Mechanisms of action
    By activating neuroprotective factors, suppresses the death of motor neurons and regulates immune response through expression of anti-inflammatory factors
  • Injection route
    intravenous administration

Cerebellar Ataxia (CA) is a rare disease in which normal movement is impossible to the extent that it is difficult to walk due to incomplete muscle movement due to damage to the cerebellum. Cerebellar ataxia is a disorder of the motor neuron, which is a disorder of the motor nervous system, and walking or staggering like a drunk person at all. It is characterized by being unable to walk and may accompany speech impairment. Although the exact cause and process of onset have not been identified yet, in some cases, there are genetic causes, neurodegenerative causes, and symptoms like Parkinson's disease. In the case of neurodegenerative cerebellar ataxia, it develops after middle age and is a relatively slow progression of late-onset cerebellar ataxia (Late-onset cerebellar ataxia, or Sporadic adult onset ataxia), which is characterized by only symptoms of cerebellar ataxia, and is accompanied by autonomic abnormalities and ataxia. Progressive multi-system atrophy cerebellar variant (MSA-C) is a representative disease. Secondary causes can be caused by various secondary causes such as endocrine disease, vitamin deficiency, alcoholism, drug toxicity, infection, and stroke.

Bone marrow-derived mesenchymal stem cells, the main component, secrete neuroprotective factors to suppress the death of motor neurons and show therapeutic efficacy by regulating the immune response through the expression of anti-inflammatory factors.